Value of CA 15:3 in the follow-up of breast cancer patients.

CA 15:3, a new tumour marker detectable by two monoclonal antibodies (115 D 8 and DF 3), was measured by an immunoradiometric technique on the ELSA solid phase. Sixteen percent of patients with localized breast cancer had CA 15:3 levels greater than 25 U ml-1, and levels increased with tumour size....

Descripción completa

Detalles Bibliográficos
Autores principales: Pons-Anicet, D. M., Krebs, B. P., Mira, R., Namer, M.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1987
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001716/
https://www.ncbi.nlm.nih.gov/pubmed/3475109
_version_ 1782135661378142208
author Pons-Anicet, D. M.
Krebs, B. P.
Mira, R.
Namer, M.
author_facet Pons-Anicet, D. M.
Krebs, B. P.
Mira, R.
Namer, M.
author_sort Pons-Anicet, D. M.
collection PubMed
description CA 15:3, a new tumour marker detectable by two monoclonal antibodies (115 D 8 and DF 3), was measured by an immunoradiometric technique on the ELSA solid phase. Sixteen percent of patients with localized breast cancer had CA 15:3 levels greater than 25 U ml-1, and levels increased with tumour size. CA 15:3 levels greater than 25 U ml-1 were found in 54% of patients with nodal involvement and in 91% of patients with metastatic breast disease. Measurement of CA 15:3 in 70 women with metastatic breast cancer and a normal CEA revealed positive CA 15:3 levels at diagnosis of the first metastasis in 66% of cases; 63% of these patients could be monitored with CA 15:3.
format Text
id pubmed-2001716
institution National Center for Biotechnology Information
language English
publishDate 1987
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20017162009-09-10 Value of CA 15:3 in the follow-up of breast cancer patients. Pons-Anicet, D. M. Krebs, B. P. Mira, R. Namer, M. Br J Cancer Research Article CA 15:3, a new tumour marker detectable by two monoclonal antibodies (115 D 8 and DF 3), was measured by an immunoradiometric technique on the ELSA solid phase. Sixteen percent of patients with localized breast cancer had CA 15:3 levels greater than 25 U ml-1, and levels increased with tumour size. CA 15:3 levels greater than 25 U ml-1 were found in 54% of patients with nodal involvement and in 91% of patients with metastatic breast disease. Measurement of CA 15:3 in 70 women with metastatic breast cancer and a normal CEA revealed positive CA 15:3 levels at diagnosis of the first metastasis in 66% of cases; 63% of these patients could be monitored with CA 15:3. Nature Publishing Group 1987-05 /pmc/articles/PMC2001716/ /pubmed/3475109 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Pons-Anicet, D. M.
Krebs, B. P.
Mira, R.
Namer, M.
Value of CA 15:3 in the follow-up of breast cancer patients.
title Value of CA 15:3 in the follow-up of breast cancer patients.
title_full Value of CA 15:3 in the follow-up of breast cancer patients.
title_fullStr Value of CA 15:3 in the follow-up of breast cancer patients.
title_full_unstemmed Value of CA 15:3 in the follow-up of breast cancer patients.
title_short Value of CA 15:3 in the follow-up of breast cancer patients.
title_sort value of ca 15:3 in the follow-up of breast cancer patients.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001716/
https://www.ncbi.nlm.nih.gov/pubmed/3475109
work_keys_str_mv AT ponsanicetdm valueofca153inthefollowupofbreastcancerpatients
AT krebsbp valueofca153inthefollowupofbreastcancerpatients
AT mirar valueofca153inthefollowupofbreastcancerpatients
AT namerm valueofca153inthefollowupofbreastcancerpatients

Ejemplares similares